The Readout LOUD

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

Party in biotech land and AstraZeneca’s miscalculation

The Readout LOUD Allison DeAngelis and Elaine Chen

A pharma C-suite shakeup and Trump’s deal with Pfizer

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

A gene therapy success in Huntington’s and Trump’s autism announcement

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Pharma sours on the U.K., plus biotech M&A’s quiet roll

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

Trump, Chinese biotech, and an industry career reshaped by illness

The Readout LOUD Allison DeAngelis, Elaine Chen, and Adam Feuerstein

New stakes in the vaccine dispute and a boost for biotech

The Readout LOUD Elaine Chen, Allison DeAngelis, and Adam Feuerstein

The ouster of CDC’s director, biotech venture firm rankings

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

Viking’s obesity flop, ‘pharma to table’ drug sales

The Readout LOUD Allison DeAngelis and Elaine Chen

Vinay Prasad’s return, animal testing alternatives, and mRNA upended

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

Closing a zombie biotech, and Lilly’s disappointing obesity readout

The Readout LOUD Elaine Chen, Adam Feuerstein, and Matthew Herper

What Vinay Prasad’s ouster means for biotech and the FDA

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

A mother’s perspective on Sarepta’s gene therapy halt

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Inside an FDA drug rejection, and layoffs at Sarepta

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

NIH grant cuts, FDA transparency questions, and biotech M&A

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

FDA’s gene therapy turmoil, and an alternative model for funding research

The Readout LOUD Adam Feuerstein and Elaine Chen

STAT Plus: A vaccine expert explains why she’s ‘very worried’ about RFK Jr. and new CDC vaccine advisers

The Readout LOUD Elaine Chen and Adam Feuerstein

The upheaval of CDC’s vaccine panel, and drug pricing confusion

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

An AI experiment at the FDA & Novo trailing in the obesity drug race

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Moderna’s vaccine hit, the MAHA report, and an ASCO preview

The Readout LOUD Allison DeAngelis, Elaine Chen, and Adam Feuerstein

Uncertainty in CRISPR world and the start of more M&A

The Readout LOUD Elaine Chen and Adam Feuerstein

Trump’s drug-pricing plan and a potential Theranos 2.0

The Readout LOUD Allison DeAngelis and Adam Feuerstein

A firebrand takes oversight of vaccines, gene therapies

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

Assessing the impact of Trump’s first 100 days on science and health policy

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

Pharma tariffs, and a ‘sunshine day’ for biotech stocks

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

BIO’s John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

Cuts, ousters and drama at the FDA

Allison DeAngelis, Adam Feuerstein, and Elaine Chen

More HHS upheaval, 23andMe’s bankruptcy, and AI for cancer survival